In this context, several RNAi therapy-based drugs for treating a variety of disorders, from rare diseases to common conditions, have emerged, including the following FDA-approved GalNAc-siRNAs: givosiran (for acute hepatic porphyria), lumasiran (for primary hyperoxaluria), inclisiran (for hypercholesterolemia), and vutrisiran (for hereditary transthyretin-mediated amyloidosis with polyneuropathy) [39]. This evidence concerns the gene TTR and polyneuropathy.